Lisuride

Lisuride (1,1-diethyl-3-[(8-alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea) is a semisynthetic 8-alpha-ergoline derivative first synthesized by Zikan and Semonsky at the Research Institute for Pharmacy and Biochemistry in Prague in 1960 as an antimigraine agent analogous to methysergide. It was subsequently developed by Schering AG (Berlin) as a dopamine D2/D3 receptor agonist for the treatment of Parkinson's disease, hyperprolactinemia, and migraine prophylaxis, and has been marketed in multiple European, Asian, and Latin American jurisdictions under the brand names Dopergin, Cuvalit, Lysenyl, Revanil, and others. Lisuride is the most potent of the classical ergoline dopamine agonists by receptor binding affinity, with sub-nanomolar Ki values at the dopamine D2 and D3 receptors and the serotonin 5-HT1A receptor, and low-nanomolar affinity across a broad panel of monoamine targets including dopamine D1, D4, and D5 receptors, serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, alpha-1 and alpha-2 adrenergic receptors, and the histamine H1 receptor. This broad receptor engagement, sometimes characterized as "dirty drug" pharmacology, produces a clinically diverse profile that distinguishes lisuride from both the older ergoline bromocriptine and the newer non-ergoline dopamine agonists ropinirole and pramipexole.

Two pharmacological features of lisuride have attracted particular research interest in the 2020s. First, lisuride is a silent antagonist at the serotonin 5-HT2B receptor, in contrast to the ergoline dopamine agonists pergolide and cabergoline, which are 5-HT2B agonists. Because 5-HT2B receptor agonism on cardiac valvular interstitial cells is the established molecular mechanism of the fibrotic cardiac valvulopathy that led to the withdrawal of pergolide and the black-box labeling of cabergoline, the 5-HT2B antagonist profile of lisuride is associated with the absence of cardiac valvulopathy adverse drug reaction reports in pharmacovigilance databases, supporting the concept that 5-HT2B agonism (not ergoline structure per se) is the critical determinant of fibrotic risk [1]. Second, lisuride is a G protein-biased partial agonist at the serotonin 5-HT2A receptor: it activates 5-HT2A-mediated Gq/11 signaling without recruiting beta-arrestin 2, and in consequence does not produce the head-twitch response in rodents or hallucinogenic activity in humans that characterizes the structurally related lysergic acid diethylamide (LSD) and other beta-arrestin-biased 5-HT2A agonists [2, 3]. This biased signaling profile has positioned lisuride as a key pharmacological tool for dissecting the signaling pathways responsible for psychedelic versus therapeutic 5-HT2A receptor effects, and recent preclinical evidence demonstrates that lisuride exerts antidepressant-like and psychoplastogenic effects in mice through G protein-dependent mechanisms without hallucinogenic activity [3].

Pharmacokinetics of oral lisuride are characterized by complete gastrointestinal absorption, high first-pass hepatic metabolism reducing absolute oral bioavailability to 10 to 20 percent, peak plasma concentrations at 60 to 80 minutes, a short elimination half-life of approximately 2 hours, and plasma protein binding of 60 to 70 percent [4]. More than 15 metabolites have been identified. The short half-life motivated the development of continuous subcutaneous infusion protocols for advanced Parkinson's disease with motor fluctuations (lisuride was the first dopamine agonist used for chronic subcutaneous pump delivery) and transdermal patch formulations intended to provide sustained plasma concentrations and continuous dopaminergic stimulation [5, 6]. Clinical evidence in Parkinson's disease demonstrates that continuous subcutaneous lisuride infusion significantly reduces off-time and dyskinesia compared to oral levodopa, with sustained benefit over four years in prospective randomized trials [7]. Oral lisuride at doses of 0.6 to 5 mg daily has demonstrated comparable antiparkinsonian efficacy to bromocriptine in adjunctive therapy, though firm conclusions on oral efficacy are limited by the absence of large randomized controlled trials [8, 9]. The compound is well tolerated at clinical doses; the principal adverse events are nausea, dizziness, orthostatic hypotension, and psychiatric effects (hallucinations, confusion) at higher doses, consistent with the dopamine agonist class. The absence of cardiac valvulopathy signal distinguishes the safety profile from pergolide and cabergoline. This monograph reviews the chemistry, synthesis, and receptor pharmacology of lisuride; the comprehensive pharmacokinetic record across oral, subcutaneous, and transdermal routes; the clinical evidence base across Parkinson's disease, hyperprolactinemia, migraine, and emerging antidepressant indications; sourcing, reconstitution, and stack-interaction considerations; adverse-event signal and safety; and a comparative assessment of five dopamine agonist alternatives against lisuride on five competency standards.